Eaton Vance Management Has $1.92 Million Holdings in GSK plc (NYSE:GSK)

Posted by on Mar 6th, 2023

Eaton Vance Management lessened its holdings in GSK plc (NYSE:GSK – Get Rating) by 20.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,119 shares of the pharmaceutical company’s stock after selling 16,338 shares during the period. Eaton Vance Management’s holdings in GSK were worth $1,917,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pflug Koory LLC acquired a new stake in shares of GSK in the 3rd quarter worth about $26,000. Householder Group Estate & Retirement Specialist LLC purchased a new stake in GSK in the 3rd quarter valued at about $31,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in GSK by 61.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after buying an additional 368 shares during the last quarter. Cowa LLC purchased a new stake in GSK in the 1st quarter valued at about $45,000. Finally, HHM Wealth Advisors LLC increased its stake in GSK by 37.7% in the 2nd quarter. HHM Wealth Advisors LLC now owns 1,527 shares of the pharmaceutical company’s stock valued at $66,000 after buying an additional 418 shares during the last quarter. Institutional investors and hedge funds own 13.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on GSK. Bank of America lowered shares of GSK from a “neutral” rating to an “underperform” rating in a research note on Monday, December 5th. The Goldman Sachs Group began coverage on shares of GSK in a research note on Sunday, February 26th. They issued a “buy” rating for the company. JPMorgan Chase & Co. increased their price objective on shares of GSK from GBX 1,350 ($16.29) to GBX 1,400 ($16.89) in a research note on Thursday, February 2nd. UBS Group lowered shares of GSK from a “neutral” rating to a “sell” rating in a research note on Friday, November 11th. Finally, TheStreet raised shares of GSK from a “c+” rating to a “b-” rating in a research report on Friday, December 30th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $1,576.88.

GSK Stock Up 0.2 %

GSK opened at $34.66 on Monday. The company has a 50 day moving average of $35.25 and a 200 day moving average of $33.55. The company has a market cap of $70.95 billion, a PE ratio of 4.04, a price-to-earnings-growth ratio of 1.74 and a beta of 0.65. GSK plc has a 12 month low of $28.47 and a 12 month high of $46.97. The company has a current ratio of 0.91, a quick ratio of 0.68 and a debt-to-equity ratio of 1.69.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 13th. Investors of record on Friday, February 24th will be issued a $0.3404 dividend. This represents a $1.36 annualized dividend and a yield of 3.93%. The ex-dividend date of this dividend is Thursday, February 23rd. GSK’s dividend payout ratio (DPR) is presently 15.50%.

GSK Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.

Recommended Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Get Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.